Savic, L.J.; Chen, E.; Nezami, N.; Murali, N.; Hamm, C.A.; Wang, C.; Lin, M.; Schlachter, T.; Hong, K.; Georgiades, C.;
et al. Conventional vs. Drug-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma—A Propensity Score Weighted Comparison of Efficacy and Safety. Cancers 2022, 14, 5847.
https://doi.org/10.3390/cancers14235847
AMA Style
Savic LJ, Chen E, Nezami N, Murali N, Hamm CA, Wang C, Lin M, Schlachter T, Hong K, Georgiades C,
et al. Conventional vs. Drug-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma—A Propensity Score Weighted Comparison of Efficacy and Safety. Cancers. 2022; 14(23):5847.
https://doi.org/10.3390/cancers14235847
Chicago/Turabian Style
Savic, Lynn Jeanette, Evan Chen, Nariman Nezami, Nikitha Murali, Charlie Alexander Hamm, Clinton Wang, MingDe Lin, Todd Schlachter, Kelvin Hong, Christos Georgiades,
and et al. 2022. "Conventional vs. Drug-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma—A Propensity Score Weighted Comparison of Efficacy and Safety" Cancers 14, no. 23: 5847.
https://doi.org/10.3390/cancers14235847
APA Style
Savic, L. J., Chen, E., Nezami, N., Murali, N., Hamm, C. A., Wang, C., Lin, M., Schlachter, T., Hong, K., Georgiades, C., Chapiro, J., & Laage Gaupp, F. M.
(2022). Conventional vs. Drug-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma—A Propensity Score Weighted Comparison of Efficacy and Safety. Cancers, 14(23), 5847.
https://doi.org/10.3390/cancers14235847
